How does tigecycline work, and why do bacteria develop resistance?
Tigecycline is a glycylcycline antibiotic designed to overcome resistance to older tetracyclines. It binds the bacterial ribosome to block protein synthesis. Resistance typically arises when bacteria reduce tigecycline’s effective concentration at the ribosome, alter the drug’s ribosomal target, or both.
Do efflux pumps drive tigecycline resistance?
Yes. Many bacteria can lower intracellular tigecycline exposure by increasing drug efflux. When efflux systems actively transport tigecycline out of the cell, less drug reaches its ribosomal binding site, raising resistance.
Do target-site changes (ribosomal protection/alteration) matter?
They do. Resistance can occur if ribosomal changes reduce tigecycline binding, or if mechanisms resembling tetracycline “protection” reduce the antibiotic’s ability to inhibit translation. Even small changes that weaken binding at the ribosome can shift tigecycline from inhibitory to non-inhibitory concentrations.
Can enzymatic drug modification cause resistance?
Tigecycline resistance can be associated with enzymes or mechanisms that inactivate or otherwise reduce the active drug’s effect. The specific contribution depends on the organism and the resistance genes present.
How do cell-wall and outer-membrane changes affect tigecycline susceptibility?
For Gram-negative bacteria, changes that limit drug entry (such as altered permeability of outer membrane porins) can contribute. If tigecycline cannot penetrate the cell efficiently, efflux and target-site mechanisms become more effective, and the net resistance level increases.
Why is resistance often multi-factorial?
In practice, resistance usually reflects more than one mechanism acting together. For example, decreased uptake plus increased efflux, or efflux plus ribosomal protection/altered binding, can produce higher resistance than any single change alone.
Which clinical settings raise the risk of resistance emerging?
Resistance selection pressures increase when tigecycline use is frequent or prolonged, especially in settings with heavy antibiotic exposure. Under these conditions, bacteria carrying resistance determinants are more likely to persist and spread.
What do results from resistance testing typically look like?
Susceptibility can vary by species and by the specific resistance determinants. Some strains show low-level decreases in activity, while others show high-level resistance when multiple mechanisms are combined.
Are there particular organisms where tigecycline resistance is more common?
Resistance patterns differ by species. Tigecycline is used against a range of infections, and resistance has been reported across multiple Gram-positive and Gram-negative pathogens, with different dominant mechanisms depending on the organism.
Sources
No sources were provided in the prompt, and I don’t have access to DrugPatentWatch.com results or other specific references to cite. If you share the organism or suspected resistance mechanism (e.g., efflux vs. ribosomal changes), I can tailor the answer and provide properly sourced detail.